Obalon Announces First Patient Treatments at its First Company-Owned Center for Weight Loss
October 22 2019 - 8:15AM
Obalon Therapeutics, Inc. (NASDAQ:OBLN), a weight loss
solutions company with the first and only FDA-approved
swallowable, gas-filled intra-gastric balloon for non-surgical
weight loss, announces it has treated the first patients at
its Company-owned weight loss treatment center, the Obalon Center
for Weight Loss, in San Diego, California.
”We are very pleased to commence operations at the Obalon Center
for Weight Loss,” said William Plovanic, President and Chief
Financial Officer. “We opened this direct channel to treat
patients in order to improve outcomes and the access and
affordability for patients with obesity seeking to lose weight with
the Obalon Balloon System. We invented, developed,
manufactured, and now are facilitating delivery of this important
therapy with the Obalon Balloon directly to patients.”
The Obalon Center for Weight Loss is a medical facility staffed
with physicians specializing in weight loss, nutritional counselors
to help patients change their eating habits for sustainable weight
loss, and other staff to help provide safe and effective treatment
with the Obalon Balloon System.
Dr. Rita Starritt, a treating physician at the Obalon Center for
Weight Loss, said, “I am very pleased to be part of the first
Obalon Center for Weight Loss. There are so many patients with
obesity who want to lose weight but are frustrated by and have
failed conventional diet and exercise programs. The Obalon Balloon
System is an FDA-approved, scientifically proven, non-surgical
weight loss solution for people who are approximately 30 to 100
pounds overweight or have a BMI between 30 and 40. Published
results from clinical trials supporting FDA approval showed a
strong safety profile and demonstrated that patients receiving the
Obalon Balloon System had twice as much weight loss than patients
who received a placebo device with diet and exercise therapy.”
The Company expects to provide more information on the treatment
center strategy in November when it reports third quarter financial
results for the quarter ending September 30, 2019.
About Obalon Therapeutics, Inc. Obalon
Therapeutics, Inc. (NASDAQ:OBLN) is a San Diego-based company
focused on developing and commercializing novel technologies for
weight loss. For more information, please
visit www.obalon.com.
Forward-Looking Statements
To the extent that statements contained in this
press release are not descriptions of historical facts regarding
Obalon Therapeutics, they are forward-looking statements reflecting
the current beliefs and expectations of management made pursuant to
the safe harbor of the Private Securities Reform Act of 1995. Such
forward-looking statements involve substantial risks and
uncertainties that could cause Obalon Therapeutics' future results,
performance or achievements to differ significantly from those
expressed or implied by the forward-looking statements. Obalon
Therapeutics undertakes no obligation to update or revise any
forward-looking statements. For a description of the risks and
uncertainties that could cause actual results to differ from those
expressed in these forward-looking statements, as well as risks
relating to Obalon Therapeutics' business in general, please refer
to Obalon Therapeutics’ annual report on Form 10-K filed with the
Securities and Exchange Commission on February 22, 2019, Form 10-Q
filed with the Securities and Exchange Commission on July 24, 2019,
and its future periodic reports filed with the Securities and
Exchange Commission.
For Obalon Therapeutics, Inc.
Investor Contact: William Plovanic President & Chief
Financial Officer Obalon Therapeutics, Inc. Office: +1 760 607
5103wplovanic@obalon.com
Obalon Therapeutics (NASDAQ:OBLN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Obalon Therapeutics (NASDAQ:OBLN)
Historical Stock Chart
From Apr 2023 to Apr 2024